About

Betalin Therapeutics is a preclinical stage company developing an innovative therapy for diabetes treatment. This game changing technology aims to replace insulin therapy for millions of patients worldwide.

Our Story

Betalin Therapeutics is developing an Engineered Micro Pancreas (EMP) to improve the quality of life for millions of people with diabetes.

Betalin Therapeutics licensed the novel EMP technology developed at The Hebrew University of Jerusalem, Israel, in an exclusive worldwide agreement in 2015. The Hebrew University continues to partner with Betalin Therapeutics to support the research and development.

After promising in vitro results and preliminary in vivo results, Betalin Therapeutics is currently raising funding in order to further optimize the therapy in animal models, complete submission of the Investigational New Drug (IND) application to the FDA, and proceed to clinical trials. Betalin Therapeutics was recently awarded a competitive matching grant from the Office of the Chief Scientist, doubling the impact of investments made at this stage.

Team

The Betalin Therapeutics team of leading experts in the fields of diabetes and biotechnology development are based at the Hebrew University-Hadassah Medical Center campus where EMP technology was first discovered.

tema-member

Prof. Eduardo Mitrani

Chief Scientist and Head of Scientific Advisory Board

Prof. Mitrani discovered and developed Betalin Therapeutics' core technology in his lab at The Hebrew University. Previous discoveries made and developed in Prof. Mitrani’s lab have been licensed by publicly traded companies including Ontogeny (Nasdaq: CRIS) and Medgenics (Nasdaq: MDGN). He has also been a visiting scholar at Harvard and Stanford Universities and publishes in prestigious journals including Cell, Science and Nature.

tema-member

Prof. James Shapiro

Scientific Advisory Board Member

Prof. Shapiro developed the Edmonton Protocol – the most advanced treatment currently being developed for the most severe cases of Type I diabetes. He is a professor of surgery, medicine and surgical oncology, and the director of the Clinical Islet Transplant Program at the University of Alberta in Edmonton, Canada and is the Canada Research Chair in Transplant Surgery and Regenerative Medicine.

tema-member

Prof. Camillo Ricordi

Scientific Advisory Board Member

Prof. Ricordi developed the Ricordi Method – an automated method for islet cell harvesting. He is the Stacy Joy Goodman Professor of Surgery, Distinguished Professor of Medicine, Professor of Biomedical Engineering, and Microbiology and Immunology at the University of Miami Diabetes Research Institute. He has served as President of the Cell Transplant Society, Co-founder and Chairman of the National Diabetes Research Coalition, Co-founder and President of the International Association for Pancreas and Islet Transplantation and currently serves as the Director of the Diabetes Research Institute Cell Transplant Center and Responsible Head of the NIH-funded cGMP Human Cell Processing Facility.

tema-member

Prof. Yaron Ilan        

Medical Advisor
 

Prof. Ilan is the Director of the Department of Medicine at The Hebrew University Hadassah Medical Center. Prof. Ilan is an expert in diabetes and immunology and has vast experience in managing pre-clinical and clinical studies, has invented a number of drugs currently being developed by pharmaceutical companies, and has also founded several successful biomedical start-ups.

tema-member

Mr. Doron Birger

Chairman of the Board of Directors

Mr. Birger has served as the CEO of Elron Electronic Industries, Ltd. (Nasdaq: ELRNF and TASE) and was chairman and director of Given Imaging (Nasdaq: GIVN and TASE) until it was acquired by Covidien in 2014. Currently, he is a board member in MCS, Medigus, IceCure and HBL Hadasit (Traded in TASE), and Chairman of Sight Diagnostics, MST, Ioptima, Magisto and Highcon.

Problem

Today diabetes management requires a combination of medications and lifestyle changes. This is a physical, emotional and financial burden on millions of people with diabetes and their caregivers.

WHAT IS DIABETES?

When we digest food, sugar is released into our blood. That sugar needs to be absorbed into the body and used for energy. Beta cells in the pancreas make and secrete insulin, which, in turn, allows the body to absorb glucose (sugar) from the blood. When beta cells malfunction, glucose is not absorbed from the blood in a steady, healthy fashion.
Diabetes is when the beta cells do not produce enough insulin, or when the body cannot use the insulin the beta cells produce.

TYPE I DIABETES

TYPE I diabetes is when the body's own immune system attacks the cells, damaging them until they cannot do their job producing insulin. Type I diabetes is a chronic disease that requires life-long insulin supplement treatment and a strict lifestyle regimen to prevent complications like cardiovascular disease, damage to the eyes, kidneys and nerves, and premature death.
There is no cure.

TYPE II DIABETES

TYPE II diabetes is when the beta cells do produce insulin but the body can't take advantage of it to get the job done. Type II diabetes is often caused by obesity, smoking and other unhealthy behaviors. More than 30% of people with Type II diabetes take insulin. Many are able to manage or even reverse their condition with lifestyle changes, sometimes combined with other medications that make it easier for their bodies to work with the insulin they do produce.

How many people are affected by diabetes

More than 420 million people worldwide suffer from diabetes1.

No one really knows why Type I diabetes develops, but it accounts for about 10% of cases worldwide* including more than 3 million Americans2.
80 more are diagnosed every day and that number goes up every year.

Diabetes management also takes a big toll – emotionally and financially – on loved ones and other caregivers of people with diabetes.

1 World Health Organization, 2014 2 Juvenile Diabetes Research Foundation

Solution

Betalin Therapeutics' EMPs are a technological breakthrough that has the potential to improve the lives of millions of people each year.

Betalin Therapeutics' proprietary technology is a biological micro-environment for supporting the harvested islets. The combination of the harvested cells and the proprietary micro-environment is called Engineered Micro-Pancreas (EMP).

Read More

The Science

"Islet transplantation has become a feasible cell therapy procedure that aims to achieve normoglycemia in severe diabetic patients. Currently, one of the greatest challenges in this approach is early islet cell death."

News

Betalin Therapeutics is developing an exciting new solution for diabetes treatment. Check out the latest news here.

Post Image
Israel21c.org, December 2015

Israeli biomed’s novel technology could cure diabetes

Post Image
Globes, December 2015

Israeli Startup aims to End Insulin Injections

Post Image
BusinessWire.com, November 2015

Betalin Therapeutics Introduces Novel Approach to Treat Diabetes

Contact

Betalin Therapeutics is developing a cutting edge solution for diabetes. Contact us to find out how you can be a part of this exciting journey.

Patients
Betalin Therapeutics is currently in the pre-clinical phase and is not recruiting patients for clinical trials. If you are interested in participating in clinical trials in the future, watch this space for updates.

Donations
IBAN: IL38 0131 9000 0002 6120 033

Press
+972 (50) 524 9606
info@betalintherapeutics.com

Investors
+972 (77) 940 0370
moni@betalintherapeutics.com

Drop us a message

Error! Please enter your name.
Error! Please enter your valid E-mail ID.
Error! Please enter your message.
Success! Your message has been sent successfully.
Error! Sorry, error occured this time sending your message.

Other Inquiries

Join Us!

Betalin Therapeutics has licensed an exciting, cutting edge technology with the potential to radically improve the lives of millions of patients worldwide. In order to take the next steps towards that aim, we are currently raising the capital that will allow us to further optimize the therapy in animal models, complete submission of the Investigational New Drug (IND) application to the FDA, and proceed to clinical trials. To hear more about how we can revolutionize diabetes treatment together, get in touch today.

+972 (77) 940 0370
moni@betalintherapeutics.com